Small pri­vate biotechs raise mon­ey in most­ly ear­ly-stage fi­nanc­ing

A trio of biotechs is look­ing to raise funds, to ei­ther kick op­er­a­tions off or to build up re­sources.

Moat Biotech­nol­o­gy, a biotech out of Ok­la­homa City fo­cus­ing on in­tranasal or in­haled ade­n­ovirus vac­cines, an­nounced Tues­day that it raised $6.5 mil­lion in its first close — af­ter launch­ing the com­pa­ny and kick­ing off an ini­tial fund­ing round back in Sep­tem­ber.

Its co-founders — Scott Rollins and Rus­sell Rother — are for­mer Alex­ion ex­ec­u­tives, ac­cord­ing to their LinkedIn pro­files. Rollins, list­ed as one of Alex­ion’s co-founders and for­mer head of drug de­vel­op­ment, left the com­pa­ny in 2008. Rother, Alex­ion’s for­mer sci­ence chief, left in 2010.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER